Unlocking New Frontiers
in Functional Design with Glycans
The application of glycan functions is just beginning to expand. At KH Neochem, we actively pursue collaborations across diverse fields—such as drug discovery, diagnostics, and materials—by leveraging our expertise in glycan supply stability and molecular design. Why not embark on a new challenge—together with glycans?
Collaboration Models
At KH Neochem, we offer two collaborative models tailored to your development stage and specific needs:
Joint Research and Development
We collaborate by integrating our glycan technologies with your proprietary technologies to explore and create new value. From problem definition to glycan structure selection, design considerations, and evaluation, we work together seamlessly. This approach fosters a long-term co-creative relationship, merging technologies and expertise.
Technical Support and Consulting
We provide technical assistance as needed for glycan-focused development and evaluation. Our support includes supplying reagents, proposing optimized structures, and considering manufacturing methods. Through these services, we share our knowledge to facilitate smooth implementation and application development.
Collaboration Benefits
Partnering with KH Neochem to explore the potential of glycans offers numerous benefits for your organization:
BENEFIT
Development of Unique Products
The advanced functionalities of glycans contribute to differentiated development and broader application expansion.
BENEFIT
Access to a Leading Glycan Partner
KH Neochem provides comprehensive technical support encompassing glycan design, synthesis, modification, and evaluation. This enables you to confidently initiate development projects, even without in-house glycan expertise.
BENEFIT
Strengthening IP Strategies
Incorporating glycan structures and modifications into your product design contributes not only to the acquisition of new intellectual property, but also to life cycle extension of existing technologies. We are also flexible in handling intellectual property in accordance with our partners' needs.
Cases
At KH Neochem, we actively engage in collaborative research and development with a diverse range of partners across various technological domains to explore the potential of glycans. Below are some of our key partnerships:
Development of Glycan Manufacturing Technologies
Since the inception of our glycan business, we have been working together with GlyTech, Inc., a pioneer in glycan research and development. Our collaboration focuses on building glycan technologies that bring manufacturing and modification into a single, integrated process. With this approach, we aim to produce glycans stably and at large scale, and to develop high-purity products suitable for pharmaceutical applications.
Peptide Drug Discovery × Glycan Modification
We are developing next-generation peptide therapeutics by combining Veneno Technologies’ (“Veneno”) advanced peptide screening technology with our glycan expertise. Veneno’s disulfide-rich peptides*, which show outstanding target selectivity, are being coupled with glycans that improve circulation time in the bloodstream. Through this combination, we aim to create medicines that are safer and provide longer-acting benefits, ultimately leading to more patient-friendly treatments.
*Disulfide-rich peptides:
Peptides containing multiple intramolecular disulfide bonds. They are resistant to proteolytic enzymes and demonstrate high thermal stability, which makes them highly valuable lead candidates for peptide drug discovery.
Creation of Novel Drug Modalities
We are jointly promoting the development of a new therapeutic modality, LYTAC*, through integrating ProAbTech's long-acting antibody fragment platform with our precision glycan-receptor targeting technologies. By attaching specific glycans to antibody fragments that bind disease-causing proteins, we can direct these proteins to the lysosome, the cell’s degradation system, for breakdown. Through this approach, we aim to open new therapeutic possibilities for diseases that have been difficult to treat with conventional therapies.
*LYTAC:
Lysosome-targeting chimaera. A novel drug discovery strategy that harnesses the lysosome, the cell’s degradation system, to eliminate disease-causing proteins located outside the cell.
We are committed to expanding collaborative opportunities with companies and research institutions interested in glycan applications. Together, we aim to unlock new possibilities in glycoscience and its practical applications.